Avellino launches DNA test for LASIK safety

Article

Avellino Lab USA recently launched the Avellino DNA Dual Test for LASIK Safety, a genetic test that can detect both Granular Corneal Dystrophy (GCD) type 1 and Avellino Corneal Dystrophy (also known as GCD2).

Menlo Park, CA-Avellino Lab USA recently launched the Avellino DNA Dual Test for LASIK Safety, a genetic test that can detect both Granular Corneal Dystrophy (GCD) type 1 and Avellino Corneal Dystrophy (also known as GCD2).

GCD is one of the more well-known corneal dystrophies related to genetic mutations. If a patient with GCD1 undergoes vision correction surgery (e.g. LASIK, LASEK, PRK), he is at extreme risk of experiencing eventual blindness. Many patients do not show physical symptoms of the condition until later in life, so relying solely on a visual examination and family history can put patients at risk, the company says.

The Avellino DNA Dual Test is able to detect the presence of the genetic mutation for GCD, allowing the patient to take precautionary steps to postpone the progression of the condition, including avoiding vision correction surgery.

Next:Hoya introduces Sensity, light reactive lenses

Adlens presents Adlens Sundials

DrFirst, My Vision Express partner to deliver comprehensive e-Rx to ECPs

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
What to know about legislative moves that have been made through May this year.
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
Robert Maloney, MD, MA, at the 2025 Controversies in Modern Eye Care meeting
Dr Jacob Lang at the 2025 Controversies in Modern Eye Care meeting
Steven Ferrucci, OD, FAAO, at Controversies in Modern Eyecare 2025
© 2025 MJH Life Sciences

All rights reserved.